HF
CLDX icon

HRT Financial’s Celldex Therapeutics CLDX Stock Holding History

HRT Financial’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.39M Sell
37,453
-9,292
-20% -$300K ﹤0.01% 1957
2026
Q1 		$1.48M Sell
46,745
-30,895
-40% -$842K ﹤0.01% 1804
2025
Q4 		$2.11M Buy
77,640
+13,471
+21% +$355K 0.01% 1268
2025
Q3 		$1.66M Buy
64,169
+15,754
+33% +$365K 0.01% 1254
2025
Q2 		$985K Buy
48,415
+26,997
+126% +$525K ﹤0.01% 1277
2025
Q1 		$388K Buy
+21,418
New +$479K ﹤0.01% 1628
2024
Q1 		– Sell
-13,243
Closed -$525K – 2403
2023
Q4 		$525K Sell
13,243
-8,362
-39% -$246K ﹤0.01% 1334
2023
Q3 		$594K Buy
+21,605
New +$677K 0.01% 1308
2023
Q1 		– Sell
-69,796
Closed -$3.11M – 2570
2022
Q4 		$3.11M Buy
+69,796
New +$2.49M 0.04% 413
2022
Q1 		– Sell
-20,487
Closed -$791K – 3187
2021
Q4 		$791K Buy
+20,487
New +$893K ﹤0.01% 1322
2021
Q2 		– Sell
-110,306
Closed -$2.27M – 2928
2021
Q1 		$2.27M Buy
110,306
+9,387
+9% +$216K 0.02% 552
2020
Q4 		$1.77M Buy
+100,919
New +$1.82M 0.04% 364
2019
Q1 		– Sell
-5,179
Closed -$15K – 551
2018
Q4 		$15K Buy
5,179
+3,953
+322% +$19.4K ﹤0.01% 558
2018
Q3 		$8K Buy
1,226
+428
+54% +$3K ﹤0.01% 390
2018
Q2 		$6K Buy
+798
New +$10.7K ﹤0.01% 262

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRT Financial's CLDX Position: Q2 2026 in Review

HRT Financial reduced its Celldex Therapeutics (CLDX) stake by 20% in Q2 2026, selling an estimated $300K and leaving 37,453 shares worth $1.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1957.

HRT Financial first reported a position in CLDX in Q2 2018 and has held it in 15 quarters since. The position peaked at $3.11M in Q4 2022. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • HRT Financial held 37,453 shares of Celldex Therapeutics worth $1.39M as of Q2 2026.
  • HRT Financial sold 9,292 Celldex Therapeutics shares in Q2 2026, an estimated $300K.
  • Celldex Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #1957 holding.
  • HRT Financial first reported a position in Celldex Therapeutics in Q2 2018 and has held it in 15 quarters since.
  • HRT Financial's Celldex Therapeutics position peaked at $3.11M in Q4 2022.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.